ArticleScientific reports2025
Association between bipolar disorder and diabetic ketoacidosis/hyperosmolar hyperglycemic state.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Individuals with bipolar disorder have a higher prevalence of type 2 diabetes mellitus (T2DM) and are at increased risk for diabetes-related complications. However, little is known about the association between bipolar disorder and acute hyperglycemic crises, including diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS). This study aimed to evaluate whether bipolar disorder is associated with an increased risk of DKA and HHS in individuals with newly diagnosed T2DM. We conducted a retrospective cohort study using the TriNetX electronic health records network. Adults diagnosed with T2DM between 2016 and 2024 who received at least one glucose-lowering medication were included. Patients with a recorded diagnosis of bipolar disorder within one year before T2DM onset formed the exposure group, while those without bipolar disorder served as controls. Individuals with pre-existing hyperglycemic crises were excluded. Propensity score matching (1:1) was applied to balance demographic factors, body mass index, comorbidities, and medication use. The primary outcome was the incidence of DKA or HHS, analyzed using Cox proportional hazards models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). After matching (N = 39,676 per group), patients with bipolar disorder had a significantly higher risk of hyperglycemic crises (HR 1.65, 95% CI 1.45-1.88). Separate analyses revealed an increased risk of DKA (HR 1.58, 95% CI 1.37-1.82) and HHS (HR 1.95, 95% CI 1.30-2.94). Subgroup analyses suggested that the association was more pronounced in younger patients, White individuals, those with cerebrovascular disease, and those on insulin therapy. Bipolar disorder may be associated with a higher risk of acute hyperglycemic crises in patients with newly diagnosed T2DM. These findings highlight the need for integrated psychiatric and diabetes care to mitigate metabolic decompensation. Future prospective studies are warranted to further explore the mechanisms underlying this association and to develop targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.